PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

被引：0
|
作者：
Black, J. D. [1 ]
Lopez, S. [1 ]
Cocco, E. [1 ]
Bellone, S. [1 ]
Altwerger, G. [1 ]
Schwab, C. L. [1 ]
English, D. P. [1 ]
Bonazzoli, E. [1 ]
Predolini, F. [1 ]
Ferrari, F. [1 ]
Ratner, E. [1 ]
Silasi, D. A. [1 ]
Azodi, M. [1 ]
Schwartz, P. E. [1 ]
Santin, A. D. [1 ]
机构：
[1] Yale Univ, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 139卷 / 03期
关键词：
D O I：
10.1016/j.ygyno.2015.09.058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：596 / 596
页数：1
相关论文
共 50 条
  • [31] Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA
    Growdon, Whitfield
    Hernandez, Silvia F.
    Chisholm, Sarah
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo R.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 597 - 597
  • [32] Addition of mTOR inhibition to HER2 blockade results in improved antitumor activity in a preclinical model of uterine serous carcinoma with HER2 gene amplification and a gain of function mutation in PIK3CA
    Hernandez, Silvia F.
    Chisholm, Sarah
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo R.
    Growdon, Whitfield B.
    CANCER RESEARCH, 2016, 76
  • [33] Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
    Lerma, Enrique
    Catasus, Lluis
    Callardo, Alberto
    Peiro, Gloria
    Alonso, Carmen
    Aranda, Ignacio
    Barnadas, Agusti
    Prat, Jaime
    VIRCHOWS ARCHIV, 2008, 453 (02) : 133 - 139
  • [34] Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
    Enrique Lerma
    Lluis Catasus
    Alberto Gallardo
    Gloria Peiro
    Carmen Alonso
    Ignacio Aranda
    Agusti Barnadas
    Jaime Prat
    Virchows Archiv, 2008, 453 : 133 - 139
  • [35] High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients
    Ishibashi, Tomoka
    Nakayama, Kentaro
    Razia, Sultana
    Ishikawa, Masako
    Nakamura, Kohei
    Yamashita, Hitomi
    Dey, Puja
    Iida, Koji
    Kurioka, Hiroko
    Nakayama, Satoru
    Otsuki, Yoshiro
    Ishikawa, Noriyoshi
    Kyo, Satoru
    DIAGNOSTICS, 2020, 10 (01)
  • [36] Role of EGFR, HER2 and PIK3CA alterations in male breast cancer
    Rizzolo, P.
    Silvestri, V.
    Falchetti, M.
    Zanna, I.
    Palli, D.
    Ottini, L.
    EJC SUPPLEMENTS, 2010, 8 (05): : 24 - 24
  • [37] Phosphorylated HER3 levels associated with trastuzumab resistance in HER2 gene amplified uterine serous carcinoma xenograft tumors
    Hernandez, Silvia F.
    DiGloria, Celeste
    Groeneweg, Jolijn
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo
    Growdon, Whitfield
    CANCER RESEARCH, 2015, 75
  • [38] BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
    Nam, Soo Kyung
    Yun, Sumi
    Koh, Jiwon
    Kwak, Yoonjin
    Seo, An Na
    Park, Kyoung Un
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Woo Ho
    Lee, Hye Seung
    PLOS ONE, 2016, 11 (03):
  • [39] 3D culture may better represent trastuzumab resistance associated with PIK3CA mutation than 2D culture
    Tatara, Takashi
    Mukohara, Toru
    Tanaka, Rina
    Shimono, Yohei
    Toyoda, Masanori
    Kiyota, Naomi
    Hirai, Midori
    Kakeji, Yoshihiro
    Minami, Hironobu
    CANCER RESEARCH, 2017, 77
  • [40] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
12345